膀胱癌患者血浆纤溶酶原激活物抑制剂1的检测及意义

Detection of plasma level of PAI-1 and its significance in patients with bladder carcinoma

目的:测定膀胱癌患者血浆中纤溶酶原激活物抑制剂1(Plasminogen activator inhibitor-1,PAI-1)浓度变化情况,探讨PAI-1浓度在膀胱癌诊断中的作用。方法:收集膀胱癌血液标本52例,并以正常人血液标本作对照,用ELISA法检测膀胱癌患者及正常对照组血浆中PAl-1的含量,并比较其差异。结果:膀胱癌患者血浆中PA1-1含量(22.49±9.54 ng/ml)明显高于对照组(P<0.01)。PAI-1浓度在膀胱癌Ⅳ期的含量与Ⅰ、Ⅱ、Ⅲ期比均有不同程度升高(P<0.05)。结论:血浆中PAI-1的浓度升高可作为膀胱癌诊断辅助指标,也可作为膀胱癌预后指标。

Objective：To detect the variation of PAI-1 concentration in blood plasma in bladder carcinoma and explore its significance in patients with bladder carcinoma.Methods： Assay the plasma PAI-1 level in both cancer groups and control group by ELISA.Results： PAI-1 levels in plasma of bladder carcinoma groups（22.49±9.54 ng/ml） were higher than that of control group（P0.01）.The PAI-1 concentration in bladder carcinoma of phase Ⅳ was significantly higher than that of other phases（P0.01）.Conclusion： PAI-1 can be used as a auxiliary marker to detect bladder carcinoma and as a prognostic indicator.